| Document |
Document Title |
|
JPWO2005095431A1 |
The present invention is characterized in that a metal selected from an alkali metal and an alkaline earth metal is allowed to act on a pregnane derivative represented by the general formula (I) in the presence of a proton feeder, an ami...
|
|
JPWO2005095433A1 |
The present invention is characterized in that a metal selected from an alkali metal and an alkaline earth metal is allowed to act on a pregnane derivative represented by the general formula (I) in the presence of a proton feeder, an ami...
|
|
JP2008504232A |
Compositions of angiostatic agents for treating choroidal neovascularization resulting from ocular surgery or from trauma to ocular tissue and methods for their use are disclosed.
|
|
JP4048114B2 |
A method of sterilizing a pharmaceutical composition containing a suspension of a pharmaceutical comprises rapidly heating the pharmaceutical composition from ambient temperature to an elevated temperature, maintaining it at or above the...
|
|
JP4039683B2 |
A codrug composition of at least two drug compounds covalently linked to one another via a labile bond to form a single codrug composition, and methods of use of the codrug for the treatment of various medical conditions. The codrug may ...
|
|
JP4008024B2 |
Methods and compositions for interacting with the GABAA receptor complex to induce sleep in humans using certain 5 3 alpha -hydroxy-5-reduced steroid derivatives.
|
|
JP2007527381A |
The invention relates to a novel procedure for the production of a high yield of small crystalline particles of a narrow size distribution.
|
|
JP3983796B2 |
This invention provides a simplified method for converting pregnan-3,20-dione compounds to 3 alpha -hydroxy,3 beta -substituted-pregnanes. By selective use of reagents the unprotected dione is converted chemoselectively and diastereosele...
|
|
JP2007231020A |
To provide a new compound which improves the lipid barrier penetrability of a biologically active substance comprising a fatty acid such as lipoic acid and simultaneously makes a biologically active substance comprising a different fatty...
|
|
JP3960481B2 |
The invention relates to compounds of formula: wherein R1 is selected from the group consisting of fatty acid acyl groups of 12 to 30 carbon atoms and fatty alcohol groups of 12 to 30 carbon atoms, and wherein R2 is selected from the gro...
|
|
JP3950489B2 |
PURPOSE: To obtain the subject compound used for betamethasone source material, etc., by dehydrating a 17α-hydroxy-17β-cyanoandrosta-diene-3-one to an novel intermediate, bringing a CN group to a methyl ketone and methylating after epo...
|
|
JP2007153910A |
To provide a therapeutic method effective for nail mycosis, and to provide a therapeutic preparation.The present invention relates to a composition comprising (a) at least one antimycotic agent and (b) at least one film forming agent, wh...
|
|
JP3918119B2 |
PCT No. PCT/EP94/00092 Sec. 371 Date Jun. 14, 1995 Sec. 102(e) Date Jun. 14, 1995 PCT Filed Jan. 12, 1994 PCT Pub. No. WO94/16710 PCT Pub. Date Aug. 4, 1994The present invention relates to a topical oil-in-water emulsion composition comp...
|
|
JP2007512369A |
The invention encompasses a novel method of treating inflammatory disease, such as rheumatoid arthritis, and novel methods of identifying and screening for drugs useful in the treatment of inflammatory diseases and their clinical symptom...
|
|
JP3902255B2 |
To provide the subject new compound having excellent antiinflammatory action and low systemic side actions and useful e.g. for an extremely strong local antiinflammatory agent by reacting deoxymethasone, etc., with an activated aromatic ...
|
|
JP2007506681A |
The present invention provides a method of treating respiratory and allergic diseases. In particular, it provides a method for the treatment of asthma comprising administering to a subject a therapeutically effective amount of a pharmace...
|
|
JP2007063296A |
To provide a medicinal composition useful for treating human prostatic adenocarcinoma.The medicinal composition for treating human prostatic adenocarcinoma comprises a 5-α-reductase inhibiting compound of 17β-(N-t-butylcarboxamide)-5-Î...
|
|
JP2007008966A |
To provide a method for treating and preventing cancers of a specific type, such as primary and metastatic cancers and cancers refractory or resistant to conventional chemotherapy.The medicinal composition for preventing and treating can...
|
|
JP2006527736A |
Method for preparing isotonic estrogen- and gestagen-containing oil emulsion (A) for intravenous administration comprises dissolving the hormones in an oil phase then emulsifying this phase in an aqueous phase, in presence of an emulsifi...
|
|
JP2006524202A |
This invention relates to 8beta-vinyl-11beta-(omega-substituted)alkyl-estra-1,3,5(10)-
trienes of general formula I with ERbeta-antagonistic activity, process for their production, their intermediate products, pharmaceutical preparations...
|
|
JP2006523715A |
The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia or a neoplasia-related disorder in a mammal using a combination of a COX-2 inhibitor and an alkylating-type antineoplastic agent.
|
|
JP2006523687A |
A pharmaceutical composition comprising a fluoroquinolone such as ciprofloxacin, cyclodextrin, and a hydroxy acid is described. The composition may be an aqueous composition, with such aqueous compositions preferably having a pH between ...
|
|
JP2006520587A |
The invention relates to the use of a single-stranded or double-stranded nucleic acid comprising a fragment of hsgk for diagnosing hypertension, with said fragment being at least 10 nucleotides/base pairs in length and with said fragment...
|
|
JP3814312B2 |
PURPOSE: To obtain the subject new derivative having anti-glucocorticoid activity and usable in treating or preventing glucocorticoid-dependent diseases such as diabetes, hypertension and arteriosclerosis. CONSTITUTION: This new 11,12-bi...
|
|
JP2006519248A |
Disclosed is a process for the synthesis of 17²-hydroxy-7±-methyl- 19-nor-17±-pregn-5(10)-ene-20-yne-3-one (tibolone, 11) and intermediates useful for the synthesis thereof: (11).
|
|
JP2006518382A |
Methods and compositions for treating retinal edema and NPDR are disclosed.
|
|
JP2006518383A |
Formulations of glucocorticoids alone and in combination with anecortave acetate are useful for preventing and treating pathologic ocular angiogenesis and associated edema
|
|
JP2006151994A |
To provide a simple method for converting a pregnane-3,20-dione compound into a 3α-hydroxy-3β-substituted-pregnane.An unprotected dione is chemoselectively and stereoselelctively converted into a 3(R)-pregnane-3-spiro-2'-oxiran-20-one ...
|
|
JP3780007B2 |
PURPOSE: To obtain a corticosteroid 17-alkyl carbonate 21-[0]-carboxylic acid carbonic ester which has a very strong local and topical anti-inflammatory action and is effctive in treating inflammatory dermatosis by reacting a specific al...
|
|
JP3781792B2 |
PURPOSE: To obtain the subject suspension preparation containing difluprednate as an active ingredient, capable of being instilled, excellent in the stabilities of the preparation and useful for the treatment and prevention of inflammato...
|
|
JP2006131619A |
To provide an aqueous suspension for nasal drops, which is easy to prepare, with maintaining superior long-term stability, good redispersibility and high retainability after the intranasal administration, as well as having good after fee...
|
|
JP3746174B2 |
Mometasone 17- furoate is made by direct esterification of the 17- hydroxyl group of mometasone using 2-furoyl chloride in the presence of a tertiary amine and an inert solvent, without prior protection of the free 11-hydroxy function.
|
|
JP2005535691A |
The present invention is directed to the use of anercortave acetate or the alcohol thereof for the protection of visual acuity in patients with age related macular degeneration.
|
|
JP2005320257A |
To provide an emulsion-type skin care preparation for external use compounded with prednisolone valerate acetate and having excellent drug stability and usability.This oil-in-polyhydric alcohol type emulsified preparation contains (a) th...
|
|
JP2005533851A |
The subject invention provides novel HMG-CoA-reductase inhibitors. In a preferred embodiment, the HMG-CoA reductase inhibitors of the subject invention can be deactivated to a primary inactive metabolite by hydrolytic enzymes. Compounds ...
|
|
JP3710470B2 |
Method, compositions, and compounds for modulating brain excitability to alleviate stress, anxiety, insomnia and seizure activity using certain steroid derivatives that act at a newly identified site on the gamma-aminobutyric acid recept...
|
|
JP2005530679A |
A method for producing a 6α-fluorinated corticosteroid or derivative thereof by reacting a 17-hydroxy-21-ester epoxide of Formula II with a stereoselective fluorinating agent to stereoselectively form a 21-ester-17-hydroxy 6α-fluorinat...
|
|
JP2005530784A |
Methods of treating, preventing and/or managing cancer as well as diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory com...
|
|
JP2005530780A |
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokin...
|
|
JP3706104B2 |
The object of the present invention is to provide vitamin D derivatives that have excellent physiological activities as medicines, particularly as therapeutic agents for skin diseases such as psoriasis, and that have a reduced hypercalce...
|
|
JP3691487B2 |
A preventive and/or therapeutic agent for inflammatory respiratory tract diseases containing, as an active ingredient, a steroid derivative represented by the following formula (1): (wherein R represents a hydrogen atom, a halogen atom, ...
|
|
JP2005524630A |
The present invention relates to the pharmaceutical use of selective estrogen receptor modulators SERMs alone or in combination with progestins for the treatment or prevention of diseases associated with elevated cartilage degradation. I...
|
|
JP2005519852A |
The present invention relates to pharmaceutical compositions and methods of using such compositions for the treatment of inflammatory diseases of the bone and joints. The compositions comprise a catalyst for the dismutation of superoxide...
|
|
JP2005097221A |
To provide a nasal drop containing a steroidal antiinflammatory agent and having highly rapid effect.This nasal drop comprises a steroidal antiinflammatory agent and menthol. The steroidal antiinflammatory agent is preferably beclomethas...
|
|
JP2005508866A |
Ophthalmic compositions comprising an ophthalmic drug and a linear polysaccharide compound are useful for topical once-a-day administration to the eye.
|
|
JP2005504776A |
The present invention relates to the use of pregnanes in inducing analgesia, preferably without overt sedation, in a mammal in response to neuropathic pain, and compositions and kits therefore.
|
|
JP2005503383A |
The invention relates to the controlled release of preparations of therapeutic agents, for example a steroid; formulations comprising said preparations; and the use of said formulations to treat diseases such as those diseases which woul...
|
|
JP2004538294A |
6 alpha -fluorpregnanes (I), where the dotted line between positions 1 and 2 represents a single or double bond; R1 is OH, OCOR2, X, SO3R3, or an (R7)(R8)(R9)SiO- group, where X is halogen, R2 and R3 are C1-6 alkyl or phenyl optionally s...
|
|
JP2004536088A |
The present invention is a novel process for the transformation of 11beta, 17alpha dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 17-acetate (III) to 11beta,17alpha,21-trihydroxy-6alpha-methylpregna-1,4-diene-3
,20-dione 21-acetate (VI)
|
|
JP2004535805A |
The present invention is a novel process for the transformation of 17alpha-hydroxy-6alpha-methylpregn-4-ene-3,20-dione 17-acetate (I)to 11beta,17alpha,21-trihydroxy-6alpha-methylpregna-1,4-diene-3
,20-dione 21-acetate (VI)
|
